LOS ANGELES, Aug. 11, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities...
Related Questions
What is the potential financial exposure for Capricor from this lawsuit?
How likely is the case to result in a settlement versus a court judgment?
What is the expected timeline for resolution of the class action?
How will the lawsuit impact Capricor's cash flow and balance sheet?
What precedent do similar securities fraud lawsuits in the biotech sector have on stock performance?
Will this development affect investor sentiment and trading volume for CAPR?
Could the lawsuit trigger increased short‑selling or hedging activity?
How might the case influence the upcoming earnings report and guidance?
What are the comparable impacts of similar securities fraud cases on competitors' stock prices?
How will this news affect CAPR's stock volatility and options pricing (implied volatility)?